Invesco Ltd. Raises Holdings in Xencor, Inc. $XNCR

Invesco Ltd. lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 44.3% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 656,201 shares of the biopharmaceutical company’s stock after acquiring an additional 201,456 shares during the period. Invesco Ltd. owned approximately 0.92% of Xencor worth $6,982,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Xencor by 1.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 636,656 shares of the biopharmaceutical company’s stock worth $6,774,000 after purchasing an additional 6,016 shares during the period. Primecap Management Co. CA lifted its holdings in shares of Xencor by 8.6% during the first quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company’s stock worth $103,857,000 after purchasing an additional 776,580 shares during the period. US Bancorp DE lifted its holdings in shares of Xencor by 312.0% during the first quarter. US Bancorp DE now owns 10,432 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 7,900 shares during the period. XTX Topco Ltd lifted its holdings in shares of Xencor by 191.7% during the first quarter. XTX Topco Ltd now owns 54,209 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 35,627 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Xencor during the first quarter worth about $135,000.

Wall Street Analyst Weigh In

XNCR has been the subject of a number of research reports. Barclays decreased their target price on Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a report on Thursday, May 8th. Wedbush decreased their price target on Xencor from $31.00 to $26.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Wells Fargo & Company decreased their price target on Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Finally, Royal Bank Of Canada decreased their price target on Xencor from $32.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, August 21st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average target price of $23.71.

Insider Activity

In other news, Director Richard J. Ranieri sold 2,993 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares in the company, valued at $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kurt A. Gustafson sold 2,993 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director owned 20,183 shares of the company’s stock, valued at $186,087.26. This trade represents a 12.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,194 shares of company stock worth $103,209 over the last three months. 5.23% of the stock is currently owned by corporate insiders.

Xencor Trading Down 1.4%

Shares of NASDAQ:XNCR opened at $7.90 on Wednesday. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $27.24. The company has a market capitalization of $563.43 million, a PE ratio of -3.29 and a beta of 0.89. The business has a 50 day moving average of $8.31 and a two-hundred day moving average of $10.04.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.37. The company had revenue of $43.61 million during the quarter, compared to the consensus estimate of $22.59 million. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.Xencor’s revenue for the quarter was up 82.4% on a year-over-year basis. During the same period in the previous year, the company posted ($1.07) earnings per share. Equities research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.